Role of the Data and Safety Monitoring Committee (DSMC)

Statistics in Medicine

Volumn 21, Issue 19, 2002, Pages 2823-2829

  Wilhelmsen, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Blinded data; Clinical trials; Legal authorities; Monitoring; Responsibility; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLASSIFICATION; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; EXPERIENCE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MONITORING; PATIENT; PHARMACOLOGY; PHYSICIAN; QUALITY CONTROL; RESPONSIBILITY; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICS;

CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037108140     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1286     Document Type: Article

References (15)

1. Statistics in Medicine. Eds T Colton, LS Freedman, AL Johnson, D Machin. 1993; 12(5/6):415-616.
2. Friedman L. The NHLBI model: a 25-year history. Statistics in Medicine 1993; 12:425-431.
3. Armstrong PW, Furberg CD. Clinical Trial Data and Safety Monitoring Boards. The search for a constitution. Circulation 1995; 91:901-904.
4. Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent Data-Monitoring Committees in randomized clinical trials sponsored by the National Cancer Institute. Journal of Clinical Oncology 1997; 15:2736-2743.
5. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999; 354:1983-1988.
6. Freidlin B, Korn EL, George SL. Data monitoring committees and interim monitoring guidelines. Controlled Clinicial Trials 1999; 20:395-407.
7. Dixon DO, Lagakos SW. Should data and safety monitoring boards share confidential interim data? Controlled Clinical Trials 2000; 21:1-6; discussion 54-55.
8. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
9. DeMets DL, Lan KKG. Interim analyses: repeated confidence interval approach. Statistics in Medicine 1994; 13:1341-1352.
10. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPhersen K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observations of each patient: I: Introduction and design. British Journal of Cancer 1976; 34:585-612.
11. Jennison C, Turnbull BW. Interim analyses: repeated confidence interval approach. Journal of the Royal Statistical Society 1989; 51:305-361.
12. Yusuf S. Peto R, Lewis J, Collins R, Sleight P. Betablockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985; 27:335-371.
13. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 1:397-401.
14. The Cardiac Arrhythmia Suppression Trial Investigators. Mortality and morbidity in patients receiving encainide, flecainide or placebo. New England Journal of Medicine 1991; 324:781-788.
15. IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT): Results from 24 hour electrocardiograms. European Heart Journal 1986; 7:749-759.